All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Anemia, a condition characterized by insufficient hemogolobin (Hb) concentration to meet the oxygen demand of the tissue, affects nearly one-quarter of the world's population \[[@pone.0208413.ref001],[@pone.0208413.ref002]\]. Distinct Hb cut-offs to define anemia varies by age, sex, altitude, smoking, and pregnancy status and are available in guidelines put forward by the World Health Organization (WHO) \[[@pone.0208413.ref003]\]. For non-pregnant women anemia is defined as Hb\<12 g/dL \[[@pone.0208413.ref003]\]. Whereas, during pregnancy the cut-offs varies by gestation ageas a result of increased blood volume and plasma expansion, and is \<11g/dL during the first trimester, \<10.5 g/dL during the second trimester and \<11 g/dL during the third trimester. In sub-Saharan Africa (SSA) anemia is prevalent among women of reproductive age and young children \[[@pone.0208413.ref001],[@pone.0208413.ref002],[@pone.0208413.ref004]\]. In year 2011, it was estimated that 496 million (29%) non-pregnant and 32 million (38%) pregnant women had anemia globally \[[@pone.0208413.ref002]\], and the World Health Organization (WHO) set a target to reduce by 50% anemia among women of reproductive age by year 2025 \[[@pone.0208413.ref004]\].

The etiology of anemia is multifactorial with the prevalence and causes varying considerably in different areas of the world by population group, region, residence (urban or rural), socioeconomic status (SES), and general environmental factors \[[@pone.0208413.ref001],[@pone.0208413.ref005]\]. Iron is a key component of Hb, and its deficiency is estimated to be responsible for 50% of all anemia cases in SSA \[[@pone.0208413.ref002],[@pone.0208413.ref006]--[@pone.0208413.ref008]\]. Iron demands are high during pregnancy and increased parity and gravidity and short interpregnancy interval can therefore substantially reduce maternal iron reserves \[[@pone.0208413.ref009]\]. Additional risk factors include other micronutrient deficiencies (folate, vitamins B~12~ and A), malaria, soil transmitted helminths (STH), chronic infections like HIV, genetic disorders including sickle cell anemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency and, α-thalassemias as well as other inflammatory conditions \[[@pone.0208413.ref010]\].

The consequences of anemia and ID vary depending on the severity, the population groups and living conditions but includes reduced work capacity in adults and neurocognitive impairment in young children \[[@pone.0208413.ref011]\]. Furthermore, it is well established that anemia during pregnancy is associated with intrauterine growth retardation, preterm delivery \[[@pone.0208413.ref012],[@pone.0208413.ref013]\], low birthweight \[[@pone.0208413.ref012]--[@pone.0208413.ref015]\], and perinatal mortality \[[@pone.0208413.ref016]\].To address this, pregnant women in Tanzania are prescribed iron and folate supplements but compliance is poor due to side effects \[[@pone.0208413.ref017]\]. Vitamin B~12~ deficiency causes megaloblastic anemia and infant vitamin B~12~ deficiency, but it is not included in the micronutrients supplementation program because of insufficient data supporting its implementation \[[@pone.0208413.ref018]\].

Although anemia during pregnancy has been associated with adverse pregnancy outcomes, the proportion of women who are already anemic or had depleted iron stores just before conception has not been well investigated in SSA. Therefore, the aim of this study was to determine the prevalence, types and risk factors associated with preconception anemia among women of reproductive age in a rural setting of northeastern Tanzania.

Materials and methods {#sec007}
=====================

Ethical statement {#sec008}
-----------------

The study received ethical approval from the Medical Research Coordinating Committee of the National Institute for Medical Research (reference number NIMR/HQ/R.8a/Vol. IX/1717).Written informed consent or thumbprint (for illiterate women) was obtained prior to enrolment. All study procedures were performed according to good clinical and laboratory practices and the Declaration of Helsinki \[[@pone.0208413.ref019]\].

Study design and setting {#sec009}
------------------------

This cross sectional study was conducted as part of a community-based epidemiological study entitled "Foetal exposure and epidemiological transition: the role of anemia in early life for non-communicable diseases in later life" (FOETALforNCD) fromJuly 2014 to December 2016 in Korogwe and Handeni districts, Tanga region, Tanzania. The aim of theFOETALforNCD project was toevaluate fetal growth alterations, placental development, and newborn susceptibility to non-communicable diseases in later life, following exposure to maternal anemia before and during pregnancy. The study population composed of women of the reproductive age. The analyses presented here utilized baseline data from women enrolled before they became pregnant. Inclusion into this study was based on their likelihood to conceive during the study period. To be included, women had to be aged 18--40 years, not be using modern contraceptive methods (except condom), or not be sub-fertile (defined as failure to conceive for two or more consecutive years for women who were trying to become pregnant), or not be pregnant at the time of enrolment (negative urine pregnancy test, HCG Vista Care Company, Shandong China), or not have a baby less than nine months old and live in an accessible area, and be willing to receive antenatal care and deliver at Korogwe District Hospital.

Participant identification and recruitment {#sec010}
------------------------------------------

Different stakeholders including village leaders, health care providers, opinion makers as well as community members were sensitized about the study goals and aims through village and health facility meetings prior to the implementation of the FOETALforNCD study. The primary means of identifying and recruiting eligible women was through contact at the household level within each village. Trained field workers made door-to-door visits to each household to explain the study, enumerate all women of reproductive age, and issue invitation cards for them to visit the nearby health facility for screening and enrolment. Other awareness and recruitment strategies included regular home visits by trained field workers (to identify new women moving into established households) and screening women as they sought other health care services. Eligible women were informed that after conception, the intention was to follow them throughout pregnancy until delivery.

Upon conception transabdominal ultrasound (5--2 MHz abdominal probe, Sonosite TITAN and Sonosite Turbo, US High resolution, Sonosite, Bothell, WA, USA) was used to estimate gestational age (GA). Gestational age estimation was based on measurement of crown rump length in the first trimester \[[@pone.0208413.ref020]\] and head circumference in the second trimester \[[@pone.0208413.ref021]\].

From July 2014 to December 2015, 2629 women were screened for eligibility for inclusion into the FOETALforNCD study and 1415 were enrolled. Of the 1214 exclusions, 313 (25.8%) were not eligible by age, 322 (26.5%) were still using modern family planning methods, 116 (9.6%) were sub-fertile, 208 (16.6%) were already pregnant, 34 (2.8%) refused, 51(4.2%) migrated out of study area and 93 (7.7%) had a child \<9 months old, while 77 (6.3%) were excluded due to other reasons. Of the 1415women included, 72 were later excluded because venous blood was not collected, and 11 did not fulfil the inclusion criteria. Furthermore, 84 women who conceived during the follow up were excluded because; 34 were already pregnant at enrolment based on the ultrasound estimated GA and 50 had a miscarriage before the GA could be ascertained, leaving 1248 women for the present analysis ([Fig 1](#pone.0208413.g001){ref-type="fig"}).

![Flow chart of participants in FOETALforNCDprepregnancy cohort.](pone.0208413.g001){#pone.0208413.g001}

Data collection and tools {#sec011}
-------------------------

Socio-demographic data including age, educational level, marital status, and economic (household size, house ownership and type of roofing materials, main source of drinking water and its ownership (private or public),type of toilet facility) and lifestyle factors (smoking, alcohol and tea consumption)were collected using a structured questionnaire. Previous medical histories, including gynecological and obstetric details, were documented. In order to define SES, a principal component analysis was applied and the variables which showed relevant contribution (greater than 10%) to the combined SES score were regarded as the ones which sufficiently described the SES of a woman \[[@pone.0208413.ref022]\]. Variables included in the final principal component analysis were educational level, occupation, type of house ownership, roofing materials, source of domestic water and its ownership as well as the type of toilet facility. The respective SES scores were categorized in tertiles as low, medium and high.

Weight (in kilograms) was measured while on barefoot and wearing light clothes (precision 0.1kg, digital weighing scales, SecaGmbh& Co. Kg, Hamburg, Germany). Height in centimeters (cm) was measured with a stadiometer (precision 1 cm) \[[@pone.0208413.ref023]\]. Mid-upper arm circumference (MUAC) was measured on the upper right arm at the midpoint of the acromion process and the tip of the olecranon (precision 1mm). For measurement of skinfold thickness, trained staff pinched the skin above triceps muscle group to raise a double layer of skin and the underlying adipose tissue without the muscle. The HARPENDEN skinfold caliper (BATY International, England) was then applied 1 cm above and at right angle to the pinch, and a reading in millimeters (mm) taken after a few second. Waist circumference was measured just above the iliac crest in the horizontal plane, and hip circumference was measured at the point yielding the maximum circumference over the buttocks, all using a standard measuring tape to the nearest 1mm\[[@pone.0208413.ref024]\].

At enrolment, 15ml of venous blood was collected in ethylenediamine tetra acetic acid coated and plain serum tubes, transported at 2° to 8°C to the NIMR Korogwe Research Laboratory and processed within two hours of collection. To avoid photo degradation during transportation, all plain tubes were wrapped in aluminium foil. Separated serum samples were stored at -80°C and later shipped in dry ice to University Hospital Sealand, Denmark for micronutrients analysis.

Hemoglobin level was measured by using Sysmex KX-21N hematological analyzer (Sysmex Corporation Kobe, Japan).According to WHO's definition, anemia was defined as Hb\<12.0 g/dL, and further categorized as mild (10.1--11.9 g/dL), moderate (8.0--10.0 g/dL) and severe (\<8.0 g/dL) \[[@pone.0208413.ref003]\]. Microcytosis was defined as mean corpuscular volume (MCV) value \<80 fL and hypochromic as mean cell hemoglobin concentration (MCHC) value \<32 g/dL. Anemia was further classified as normocytic-normochromic (Hb\<12 g/dL, MCV 80--100 fL and MCHC\>32 g/dL), microcytic hypochromic (Hb\<12 g/dL, MCV\< 80 fL and MCHC\<32 g/dL), megaloblastic (Hb\<12g/dL, MCV≥100) or as mixed types (normocytic-hypochromic, microcytic-normochromic macrocytic-normochromic and macrocytic-hypochromic) anemia. For clinical care, Hb levels were measured using HemoCue 301 Hb analyzer (HemoCue AB, Angelholm, Sweden). Anemic women received treatments as follows: mild anemic (Hb10.1--11.9 g/dL) women with no symptoms received dietary counseling whereas women with symptoms were offered one combination tablet of 200 mg ferrous sulfate (\~ 43 mg elemental iron) and 400μg folate per day (Ferrolic--LF, Laboratory and Allied LTD, Mombasa, Kenya). Moderately anemic patients with Hb 9.1--10.0g/dL received 2--3 combination tablets of iron and folic acid (Ferrolic--LFLaboratory and Allied LTD, Mombasa, Kenya) per day and monitored at each scheduled visit. Those with Hb 8.0--9.0 g/dL received a daily dose of 20 mL Hemovit multivitamin syrup (200 mg Ferrous sulfate, 0.5mg B~6~, 50 μg B~12~, 1500 μg Folic acid and 2.33mg Zinc per 5mL, Shelys Pharmaceuticals, Dar es Salaam, Tanzania) and monitored at each scheduled visit. Severely anemic (Hb\<8g/dL) women were referred to Korogwe District Hospital for further evaluation.

Serum ferritin, vitamin B~12,~ folate, alanine aminotransferase (ALT) and bilirubin levels were measured using Dimension Vista 1500 biochemical analyzer (Siemens Healthcare Diagnostics, Inc, New York, USA) \[[@pone.0208413.ref025]\]. C-reactive protein (CRP) was measured by using Afinion AS 100 analyzer (Axis Shield PoC, AS, Oslo Norway) and inflammation defined as serum CRP \>5 mg/L and/or ALT \>45 U/L \[[@pone.0208413.ref010]\].

To account for elevated serum ferritin due to sub-clinical infection and other inflammatory conditions, three approaches were applied to define ID and results compared. The first approach utilized arithmetic correction factor (CF)as proposed by Thurnham*et al*.\[[@pone.0208413.ref026]\] to adjust for the increased serum ferritin levels due to inflammation. In this approach CF of 0.67 was applied only for samples that had evidence of inflammation (CRP\>5 mg/L), and a cut-off of \<15 μg/L was then applied to the adjusted ferritin levels to define ID. If CRP was not available, serum ferritin was coded as missing. In the second approach, a higher ferritin-cutoff (\<30μg/L) was applied to the subset of individuals with inflammation (CRP \>5 mg/L) to define ID, as proposed by the WHO \[[@pone.0208413.ref027]\]. In this approach ID was defined as serum ferritin \<15μg/L (no inflammation) or 30μg/L (inflammation present). The third approach utilized the higher serum ferritin cutoff (\<30μg/L) if CRP\>5mg/L and/or ALT\>45 U/L which is considered as a sign of liver disease \[[@pone.0208413.ref010]\]. In the core analyses presented here, ID anemia was defined as Hb\<12g/dL in the presence of ID based on Thurnham approach. Vitamin B~12~ deficiency was defined as serum cobalamin \<150 pmol/L, and folate deficiency as serum folate\<10 nmol/L without adjusting for inflammation \[[@pone.0208413.ref028]\].

Malaria was diagnosed using malaria rapid diagnostic test (mRDT) kit, ParaHIT (span diagnostics, Gujarat, India) or CareStart Malaria Pf (HPR2), ACCESS BIO, New Jersey, USA) according to manufacturer instructions. In addition, thick and thin blood films were prepared for the detection and quantification of parasitemia. Malaria patients received oral artemether-lumefantrine, (Lumartem 20mg/120mg (Cipla Ltd, Patalganga, India), quinine or artesunate injections according to Tanzanian standard treatment guideline. Human immunodeficiency virus infection was tested by using DetermineHIV-1/2 test kit (Alere ltd, Stockport, UK) and seropositive cases were confirmed using Unigold test kit (Trinity Biotech Plc, Wicklow, Ireland) according to the manufacturers' instructions. Newly diagnosed HIV patients were referred to the nearby care and treatment clinics for long-term care. Considering low prevalence of STH infestations in north eastern Tanzania \[[@pone.0208413.ref029]\], stool samples were collected from a subgroup of 434 women at the time of enrolment and preserved in 10% neutral buffered formalin solution. Formol-ether concentration technique was used to detect presence of STH infestations \[[@pone.0208413.ref030]\]. All confirmed (on stool samples)or clinical suspected cases of STH infestation received a single dose of albendazole (400mg) or mebendazole (500mg) tablets according to the existing Tanzanian standard treatment guideline.

### Statistical analysis {#sec012}

Microsoft Access software 2007 (Microsoft corporation, Redmond's, USA) was used for data entry and validation. Stata version 13 (StataCorp, Lake Way drive, College station, USA) software was used for statistical analyses. Continuous variables were visually inspected for normality using histograms and described using mean and standard deviation if normally distributed or median (interquartile range---IQR) for skewed data. Univariate analysis was done using Student's t-test or Mann-Whitney test for continuous parametric and non-parametric variables, and Chi-square (χ^2^) or Fisher\'s exact test for categorical variables. Factors associated with preconception anemia were determined using logistic regression analysis and expressed as unadjusted odds ratio (OR) and adjusted odds ratios (AOR). All variables with *P*-value \<0.20 in the univariate analysis were entered into the multivariate models \[[@pone.0208413.ref031]\]. Using a stepwise backward elimination approach final models including variables with a *P*-value \<0.10 were obtained. A *P*-value of *\<*0.05 was considered statistically significant. Due to missing data on HIV infections in 350 (28.8%) women and considering HIV infection being an important confounding factor, two different models with and without adjusting for HIV infection were generated and compared.

Finally, in order to illustrate the association between a risk factor and anemia, trendline figures were generated for each continuous risk factor found to be statistically significant or borderline significant in the multivariate model.

Results {#sec013}
=======

The baseline characteristics of the women enrolled in the study are shown in[Table 1](#pone.0208413.t001){ref-type="table"} below.

10.1371/journal.pone.0208413.t001

###### Baseline characteristics of women before pregnancy in north eastern Tanzania.

![](pone.0208413.t001){#pone.0208413.t001g}

  ----------------------------------------------------------------------------------------------------------------- ------ --------------------------- ----- -------------------------- ----- --------------------------- -----------
                                                                                                                           All                               Anemic (Hb\<12g/dL)              Non-anemic (Hb≥12g/dL)      
  Characteristics                                                                                                   N      \% (95% CI) /median (IQR)   n     \% (95% CI) /median(IQR)   n     \% (95% CI) /median (IQR)   *P*-value
  **Age (yrs)**[^**a**^](#t001fn001){ref-type="table-fn"}                                                           1233   28 (22--34)                 448   29 (22--36)                785   27.8 (22--33)               0.004
  **Ethnic group**[^**b**^](#t001fn002){ref-type="table-fn"}                                                        1247                               457                              790                               0.021
  Sambaa                                                                                                                   34.0 (31.4--36.7)                 38.3(33.9--42.9)                 31.5 (28.4--34.9)           
  Zigua                                                                                                                    32.5 (29.9--36.7)                 32.4 (28.2--36.8)                32.5 (29.3--35.9)           
  Others[^**b**^](#t001fn002){ref-type="table-fn"}                                                                         33.5 (30.9--36.2)                 29.3 (25.3--33.8)                36.0 (32.7--39.4)           
  Parity[^**b**^](#t001fn002){ref-type="table-fn"}                                                                  1242                               456                              786                               0.067
  0                                                                                                                        18.4 (16.4--20.7)                 18.4 (12.1--22.3)                18.4 (15.9--21.))           
  1                                                                                                                        38.7 (36.1--41.5)                 35.5 (31.3--25)                  40.6 (37.2--31.4)           
  2                                                                                                                        16.5 (14.5--18.7)                 16.0 (12.9--19.7)                16.8 (14.3--19.6)           
  3                                                                                                                        12.4 (10.7--14.4)                 12.3 (12.0--15.9)                15.0 (12.5--14.8)           
  \>3                                                                                                                      13.9 (12.1--16.0)                 17.5 (14.3--21.3)                11.8 (9.8--14.3)            
  **House hold size (numbers)**[^**a**^](#t001fn001){ref-type="table-fn"}                                           1243   4.0 (3.6)                   457   4 (3--6)                   786   4 (3--6)                    0.31
  **Education level**[^**b**^](#t001fn002){ref-type="table-fn"}                                                     1247                               457                              790                               0.12
  No education                                                                                                             8.1(6.7--9.8)                     9.0 (6.7--12.0)                  7.6 (5.9--9.7)              
  Primary incomplete                                                                                                       11.2 (9.5--13.1)                  11.4 (8.8--14.6                  11.1(9.1--13.5)             
  Primary school complete                                                                                                  63.1(60.4--65.8)                  65.4 (60.9--69.7)                61.8 (58.3--65.1)           
  Secondary or higher                                                                                                      17.6 (15.5--19.8)                 14.2 (11.3--17.7)                19.5 (16.9--22.4)           
  **Occupation**[^**b**^](#t001fn002){ref-type="table-fn"}                                                          1247                               457                              790                               0.53
  Professional                                                                                                             3.1(2.2--4.2)                     3.3 (2.0--5.4)                   2.9 (1.9--4.3)              
  Business                                                                                                                 3.4 (2.6--4.6)                    3.5 (2.2--5.6)                   3.4 (2.4--4.9)              
  Service provider                                                                                                         15.2 (13.3--17.3)                 12.9 (10.1--16.3)                16.6 (14.1--19.3)           
  Farmer                                                                                                                   57.2 (54.4--59.9)                 59.1 (54.4--63.5)                56.1 (52.6--59.5)           
  House wife/student                                                                                                       21.1(19.9--223.4)                 21.2 (17.7--25.2)                21.0 (18.3--24.0)           
  **Type of house ownership**[^**b**^](#t001fn002){ref-type="table-fn"}                                             1242                               456                              786                               0.21
  Self/spouse built                                                                                                        64.3 (61.6--67.0)                 66.5 (62.0--70.6)                63.1 (59.7--66.4)           
  Inherited                                                                                                                15.7 (13.8--17.8)                 16.2 (13.1--19.9)                15.4 (13.0--18.1)           
  Rental                                                                                                                   20.0 (17.8--22.3)                 17.3(14.1--21.1)                 21.5 (18.8--24.5)           
  **Roofing materials**[^**b**^](#t001fn002){ref-type="table-fn"}                                                   1247                               457                              790                               0.36
  Iron                                                                                                                     74.0 (71.0--76.3)                 73.3 (69.0--77.2)                74.3 (71.1--77.2)           
  Tin                                                                                                                      0.6 (0.3--1.3)                    0.2 (0.03--1.5)                  0.9 (0.4--1.8)              
  Asbestos                                                                                                                 1.1(0.6--1.8)                     1.5 (0.7--3.2)                   0.9 (0.4--1.8)              
  Thatch/mixed                                                                                                             24.3 (22.0--26.8)                 25.0 (21.2--29.1)                23.9 (21.1--27.0)           
  **Source of domestic water** [^**b**^](#t001fn002){ref-type="table-fn"}                                           1244                               455                              786                               0.64
  Private tap                                                                                                              7.7 (6.4--9.4)                    8.5 (6.3--11.5)                  7.2 (5.6--9.3)              
  Private bore hole                                                                                                        0.8 (0.4--1.5)                    1.1 (0.4--2.6)                   0.6 (0.3--1.5)              
  Public tap                                                                                                               53.7 (50.9--56.4)                 51.6 (47.0--56.2)                54.6 (51.1--58.2)           
  Public bore hole                                                                                                         11.5 (9.9--13.4)                  11.0 (8.4--14.2)                 12.0 (9.7--14.3)            
  River/pool                                                                                                               26.3 (23.9--28.8)                 27.8 (23.9--32.1)                25.6 (22.7--28.8)           
  **Type of toilet facility**[^**b**^](#t001fn002){ref-type="table-fn"}                                             1246                               456                              790                               0.38
  Flush                                                                                                                    25.0 (22.7--27.5)                 23.9 (20.2--28.1)                25.7 (22.8--28.9)           
  Pit                                                                                                                      74.1 (71.6--76.4)                 74.8 (70.6--78.6)                73.7 (70.5--76.6)           
  None                                                                                                                     0.9 (0.5--1.6)                    1.3 (0.6--2.9)                   0.6 (0.3--1.5)              
  **Socioeconomic status**[^**b**^](#t001fn002){ref-type="table-fn"}^,^[^**b**^](#t001fn002){ref-type="table-fn"}   1235                               453                              782                               0.25
  High                                                                                                                     33.5 (30.9--36.2)                 35.5 (31.2--40.1)                32.3 (29.2--35.7)           
  Medium                                                                                                                   33.4 (30.8--36.0)                 34.2 (30.0--38.7)                32.9 (29.7--36.2)           
  Low                                                                                                                      33.1 (30.5--35.8)                 30.2 (26.2--34.6)                34.8 (31.5--38.2)           
  **Bed net ownership (Yes)**[^**b**^](#t001fn002){ref-type="table-fn"}                                             1247   78.8 (76.5--81.0)           457   77.2 (72.3--80.9)          790   79.7 (76.8--82.4)           
  **MUAC (cm)** [^**a**^](#t001fn001){ref-type="table-fn"}                                                          1242   27.9 (25.8--31)             453   27.4 (25.4--29.9)          789   28 (26--31.5)               0.0003
  **Waist circumference (cm)**[^**a**^](#t001fn001){ref-type="table-fn"}                                            1218   80.0 (74.1--87.8)           444   79.2 (74.2--86.1)          774   80.3 (74--89)               0.06
  **Hip circumference(cm)**[^**a**^](#t001fn001){ref-type="table-fn"}                                               1234   94.5 (89--101.2)            454   94 (88.1--99.5)            780   95 (89.4--102.1)            0.01
  **Body mass index (kg/m**^**2**^**)**[^**a**^](#t001fn001){ref-type="table-fn"}                                   1231   22.7 (20.5--26.3)           449   22.1 (20.2--25.2)          782   23.0 (20.7--26.7)           0.036
  **Body mass index categories**                                                                                                                                                                                          
  Underweight                                                                                                       1231   8.0 (6.6--9.7)                    9.4 (7.0--12.4)                  7.2 (5.7--9.3)              
  Normal weight                                                                                                            60.5 (57.8--63.2)                 63.9 (59.4--68.2)                58.9 (55.1--62.0)           
  Overweight                                                                                                               20.2 (18.1--22.6)                 18.0 (14.7--21.9)                21.5 (18.7--24.5)           
  Obesity                                                                                                                  11.2 (9.6--13.1)                  8.7 (6.4--11.7)                  12.7 (10.5--15.3)           
  **Previous use of hormone contraceptives**[^**b**^](#t001fn002){ref-type="table-fn"}                              1248   71.5 (68.9--73.9)           458   32.5 (63.0--77.6)          790   26.2 (23.2--29.4)           0.017
  **Length of menstrual periods**[^**b**^](#t001fn002){ref-type="table-fn"}                                         1217   4 (3--5)                    446   4 (3--5)                   771   4 (3--5)                    0.104
  **Length of menstrual cycle (days)**[^**b**^](#t001fn002){ref-type="table-fn"}                                    1162                               428                              734                               0.144
  Normal (25--35)                                                                                                          85.7 (83.6--87.6)                 84.1 (80.3--87.3)                86.7 (84.0--88.9)           
  Short (\<25)                                                                                                             2.9 (2.1--4.1)                    2.3 (1.2--4.3)                   3.3 (2.2--4.8)              
  Long (≥35)                                                                                                               11.4 (9.7--13.3)                  13.6 (10.6--17.1)                10.0 (8.1--12.5)            
  **Self-reported malaria last 2 months**[^**b**^](#t001fn002){ref-type="table-fn"}                                 1234   22.7 (20.4--25.1)           452   26.1(22.3--30.4)           782   20.7 (18.0--23.7)           0.029
  **Malaria at enrolment**[^**b**^](#t001fn002){ref-type="table-fn"}                                                1244   8.1 (6.7--9.8)              456   10.3 (7.8--13.4)           788   6.9 (5.3--8.8)              0.032
  **HIV seropositive**[^**e**^](#t001fn005){ref-type="table-fn"}                                                    952    5.7 (4.4--7.3)              344   9.0 (6.4--12.6)            608   3.8 (2.5--5.6)              0.004
  **Intestinal helminths infestations**[^**b**^](#t001fn002){ref-type="table-fn"}                                   434    3.0 (1.7--5.1)              147   1.4 (0.3--5.4)             287   4.9 (2.1--6.8)              0.64
  **Inflammation (CRP\>5mg/L)**[^**b**^](#t001fn002){ref-type="table-fn"}                                           1229   15.2 (13.3--17.3)           448   18.5 (15.2--22.4)          781   13.3 (11.1--15.9)           0.014
  **Hemoglobin (g/dL)(mean±se)**                                                                                    1248   12.2±0.04                   458   10.7±0.06                  790   13.1±0.03                   \<0.001
  **RBC morphological types**[^**b**^](#t001fn002){ref-type="table-fn"}                                                                                                                                                   
  Normocytic-normochromic                                                                                           1248   56.3 (53.6--59.3)           458   32.8 (28.6--37.2)          790   70.0 (66.7--73.1)           \<0.001
  Microcytic-hypochromic                                                                                            1248   17.5 (15.5--19.8)           458   38.2 (33.9--42.8)          790   5.6 (4.2--7.4)              
  Microcytic-normochromic                                                                                           1248   19.9 (17.7--22.2)           458   19.0 (15.6--22.9)          790   20.4 (17.7--23.3)           
  Normocytic-hypochromic                                                                                            1248   5.9 (4.7--7.4)              458   9.8 (7.4--12.9)            790   3.7 (2.6--5.2)              
  Megaloblastic                                                                                                     1248   0.3 (0.1--0.8)              458   0.2 (0.03--1.5)            790   0.4 (0.1--1.4)              
  **Micronutrient status**                                                                                                                                                                                                
  s-ferritin (μg/L)[^**a**^](#t001fn001){ref-type="table-fn"}                                                       1245   22.3 (10.1--39.7)           457   11.3 (5.4--28.4)           788   27.3 (15.2--43.8)           \<0.001
  Iron deficiency [^**b**^](#t001fn002){ref-type="table-fn"}                                                        1226   37.6 (34.9--40.4)           447   58.8 (54.2--63.3)          779   25.4 (22.5--28.6)           \<0.001
  s-Folate (nmol/L)[^**a**^](#t001fn001){ref-type="table-fn"}                                                       1194   30.8 (21--39.3)             448   28.8 (19.7--37.8)          746   32.2 (22.4--40.4)           0.0003
  Folate deficiency[^**b**^](#t001fn002){ref-type="table-fn"}                                                       1194   2.1 (1.4--2.9)              448   3.1 (1.8--5.2)             746   1.5 (0.8--2.6)              0.043
  s-Vitamin B~12~(pmol/L)[^**a**^](#t001fn001){ref-type="table-fn"}                                                 1245   465.2 (343--613.4)          457   455.8 (332.7--591.7)       788   470.9 (347.7--626.8)        0.07
  Vitamin B12 deficiency[^**b**^](#t001fn002){ref-type="table-fn"}                                                  1245   0.6 (0.3--1.2)              457   0.4 (0.1--1.7)             788   0.6 (0.2--1.5)              0.65
  **Time from enrolment to conception (days)**[^**f**^](#t001fn006){ref-type="table-fn"}                            259    87 (38--157)                91    85 (32--143)               168   91 (40--160)                0.48
  **Adverse pregnancy outcomes**[^**g**^](#t001fn007){ref-type="table-fn"}                                          249    34.1 (28.5--40.3)           86    34.9 (25.4--45.7)          163   33.7 (26.8--41.4)           0.86
  ----------------------------------------------------------------------------------------------------------------- ------ --------------------------- ----- -------------------------- ----- --------------------------- -----------

^a^Median (IQR)

^b^ Percentage (95% CI)

^c^Other ethnic group comprised of 56 minority groups that constituted \<10% of the total study population per group.

^d^Socio-economic status was determined using principal components analysis based on woman education level, occupation, main source of domestic water, type of house ownership, roofing materials and type of toilet facility. Low scores for SES were given for no education/partial primary education, occupation as housewife/farmer, pond/river, rental housing, thatch roofing, or having no toilet.

^e^ HIV infection was tested only for women who consented after voluntary counseling. Iron deficiency was based on Thurnham*et al*. approach \[[@pone.0208413.ref026]\]. There were no mixed microcytic and macrocytic RBC morphological types.

^f^ During the study period 259 women conceived and had gestational age estimated using ultrasound and data during pregnancy available. Women conceiving after the end of the study did not provide data for these analyses.

^g^ Adverse pregnancy outcomes include miscarriage, low birthweight, prematurity, small for gestational age (\<10^th^percentile on the STOPPAM reference chart)\[[@pone.0208413.ref032]\] or stillbirth.

**Abbreviations:** Hb: Hemoglobin; MUAC: Mid-upper arm circumference; RBC: Red blood cell; CRP: C---reactive protein

The median (IQR) age of the women was 28.2 (IQR = 22--34) years. Few women were underweight (8.0%), while 60.5%, 20.2% and 11.2%, were normal weight, overweight and obese, respectively. Majority (71.5%) had previously used at least one type of hormonal contraceptive. Malaria infection was detected in 8.1% (95% CI 6.7--9.8) of the women while 5.7% (95% CI 4.4--7.3), 3.0% (95% CI 1.7--5.1) and 15.2% (95% CI 13.3--17.3) had STH infestations, HIV and inflammation, respectively.

The mean±seHb level was 12.2±0.04 g/dL and 36.7% (95% CI 34.1--39) women had anemia ([Table 1](#pone.0208413.t001){ref-type="table"}). Severe, moderate, and mild anemia were found in 1.8%, 95% CI 1.8--2.7), 16.1% (95% CI 14.2--18.3 and 18.8% (95% CI 16.8--21.1) of women, respectively (data not shown). Comparing anemic and non-anemic women, there was a statistically significant difference in age, ethnicity, MUAC, waist and hip circumference, BMI, and self-reported or malaria infection at the time of enrolment ([Table 1](#pone.0208413.t001){ref-type="table"}). Overweight (BMI of 25-\<30kg/m^2^) and obesity (BMI≥30 kg/m^2^) were observed in 20.2% (95% CI 18.1--22.6%) and 11.2% (95% CI 9.6--13.1) of the women, respectively. The coexistence of overweight and obesity with anemia was found in 81/449 (18.0%) and 39/449(8.6%) of women, respectively ([Table 1](#pone.0208413.t001){ref-type="table"}) while79/451 (17.5%) and 42/451 (10.0%) of iron deficient women had concurrent overweight and obesity, respectively (data not shown).

When using the internal CF approach by Thurnham*et al*., 37.6% (95% CI 34.9--40.4) women had ID. Using the WHO definition (serum ferritin \<15 μg/L or \<30 μg/L in the presence of inflammation), 39.2% (95% CI 36.5--41.9) were classified as having ID. After further adjustment to account for liver disease (serum ferritin \<15μg/L or \<30μg/L in the presence of inflammation (CRP \>5 mg/Land ALT \>45 U/L), 40.2% (95% CI 37.5--43.0) women were classified as having ID. Of the 458 women with anemia 58.8% (95% CI 54.2--63.3), 3.1% (95% CI 1.8--5.1) and 0.4% (95% CI 0.1--1.7) had concurrent iron, folate and vitamin B~12~ deficiencies, respectively ([Table 1](#pone.0208413.t001){ref-type="table"}). Based on Thurnham approach, among 461 women with ID, only 2.2% (95% CI 1.2--4.1) had combined iron and folate deficiency and 0.4% (95% CI 0.1--1.7) had combined iron and vitamin B~12~ deficiencies, while none had combined folate and Vitamin B~12~ deficiency (data not shown).Finally, concurrent ID with malaria, HIV and inflammation were found in 2.8% (95% CI 1.7--4.8), 4.7% (95% CI 3.0--7.5), and 11.7% (95% CI 9.1--15.1), respectively (data not shown).

The majority of the women (56.3%, 95% CI 53.6--59.3) had normocytic-normochromic RBC morphology, while 17.5% (95% CI 15.5--19.8), 19.9% (95% CI 17.7--22.2), 5.9% (95% CI 4.7--7.4) and 0.2% (95% CI 0.1--0.8) had microcytic-hypochromic, microcytic-normochromic, normocytic-hypochromic and megaloblastic RBC morphology, respectively. However, for the anemic women, only 32.8% (95% CI 28.6--37.2) had normocytic-normochromic while 38.2% (95% CI 33.9--42.8), 19.0% (95% CI 15.6--22.9), 9.8% (95% CI 7.4--12.9) and 0.2% (95% CI 0.03--1.5) had microcytic-hypochromic, macrocytic normochromic, normocytic-hypochromic and megaloblastic RBC morphology, respectively ([Table 1](#pone.0208413.t001){ref-type="table"}). Interestingly, among the ID anemic women (Hb\<12g/dL and serum ferritin \<15μg/L), only 48.7% (95% CI 42.6--54.7) had microcytic-hypochromic RBC morphological pattern, whereas 25.5% (95% CI 20.5--31.1), 20.6% (95% CI 17.1--24.6) and 6.5% (95% CI 4.5--9.2) had normocytic-normochromic, microcytic-normochromic and normocytic-hypochromic RBC morphological types, respectively (data not shown).

The results of the univariate and multivariate logistic regression analysis with all variables entered into the model except HIV infection are shown in [Table 2](#pone.0208413.t002){ref-type="table"} below.

10.1371/journal.pone.0208413.t002

###### Risk factors associated with preconception anemia among women in rural north eastern Tanzania (N = 1125) [^a^](#t002fn001){ref-type="table-fn"}.

![](pone.0208413.t002){#pone.0208413.t002g}

                                                 Unadjusted          Adjusted[^b^](#t002fn002){ref-type="table-fn"}                       
  ---------------------------------------------- ------------------- ------------------------------------------------ ------------------- ---------
  **Age(years)**                                 1.03 (1.01--1.04)   0.003                                            1.05 (1.03--1.07)   \<0.001
  **Ethnic group**                                                                                                                        
  Sambaa                                         Ref.                                                                 Ref.                
  Zigua                                          0.82 (0.62--1.08)   0.163                                            0.82 (0.59--1.13)   0.231
  Others[^c^](#t002fn003){ref-type="table-fn"}   0.67 (0.51--0.89)   \<0.001                                          0.63 (0.45--0.87)   0.005
  **Parity**                                                                                                                              
  0                                              Ref.                                                                 Ref.                
  1                                              0.75 (0.51--1.09)   132                                              0.80 (0.49--1.31)   0.382
  2                                              1.04 (0.71--1.53)   0.828                                            1.16 (0.67--1.99)   0.597
  3                                              0.96 (0.64--1.41)   0.817                                            1.01 (0.55--1.86)   0.981
  ≥4                                             1.24 (0.88--1.76)   0.226                                            1.13 (0.59--2.16)   0.703
  **MUAC (cm)**                                  0.95 (0.92--0.98)   \<0.001                                          0.90 (0.84--0.96)   0.002
  **Waist circumference (cm)**                   0.99 (0.98--0.99)   0.03                                             1.02 (0.98--1.06)   0.698
  **Hip circumference (cm)**                     0.98 (0.97--0.99)   0.007                                            1.02 (0.99--1.05)   0.060
  **Body Mass Index**                            0.96 (0.93--0.98)   \<0.001                                          0.97 (0.89--1.07)   0.589
  **Previous use of hormonal contraceptives**    0.74 (0.57--0.95)   0.017                                            0.74 (0.54--1.00)   0.053
  **Length of menstrual periods**                1.09 (1.01--1.17)   0.035                                            1.05 (0.96--1.16)   0.269
  **Length of menstrual cycles (days)**                                                                                                   
  Normal (25--35)                                Ref                                                                  Ref                 
  Short (\<25)                                   1.38 (0.96--2.00)   0.082                                            1.26 (0.81--1.95)   0.298
  Long(≥35)                                      0.73 (0.35--1.56)   0.423                                            0.82 (0.34--2.01    0.668
  **Self-reported malaria last two months**      1.35 (1.03--1.77)   0.035                                            1.34 (0.98--1.84)   0.068
  **Malaria at enrolment**                       1.56 (1.04--2.35)   0.033                                            2.21 (1.37--3.58)   0.001
  **Inflammation**                               1.48 (1.08--2.03)   0.015                                            1.77 (1.21--2.60)   0.003
  **Iron deficiency**                            4.19 (3.27--5.37)   \<0.001                                          4.68 (3.55--6.17)   \<0.001
  **Folate deficiency**                          2.15 (0.87--5.29)   0.059                                            2.15 (0.87--5.29)   0.097

^a^Final model consisted of 1125 observations due to some missing values

^b^Only variables with p\<0.1 were retained in the final multivariate analysis model.

^c^Other ethnic group comprised of 56 minority groups that constituted \<10% of the total study population per group. Iron deficiency was based on Thurnham*et al*. approach \[[@pone.0208413.ref026]\].

**Abbreviation:** MUAC: Mid-upper arm circumference.

In the univariate analysis, women from the minority tribes, increased MUAC, waist and hip circumferences, BMI as well as previous use of hormonal contraceptives, were statistically significantly associated with reduced risk of anemia. Increasing age, length of menstrual periods, malaria infection before or at the time of enrolment, inflammation and ID were significantly associated with increased risk of anemia ([Table 2](#pone.0208413.t002){ref-type="table"}). Skinfold thickness showed similar associations with risk of anemia as MUAC but data was missing on 25% of the women and were therefore not included in further analyses (data not shown).

In the multivariate logistic regression analysis, women from the minority tribes (adjusted OR (AOR) 0.63, 95% CI 0.45--0.87) and increased MUAC (AOR 0.90, 95% CI 0.84--0.96) remained statistically significantly associated with reduced odds of having anemia while previous use of hormonal contraceptives was marginally protective against anemia (AOR 0.74, 95% CI 0.54--1.00). Increased age (AOR 1.05, 95% CI 1.03--1.07), malaria infection at the time of enrolment (AOR) 2.21, 95% CI 1.37--3.58), inflammation (AOR 1.77, 95%, CI 1.21--2.60), and ID (AOR 4.68, 95% CI 3.55--6.17 were all statistically significantly associated with increased risk of anemia ([Table 2](#pone.0208413.t002){ref-type="table"}). A model including HIV was also generated ([S1 Table](#pone.0208413.s001){ref-type="supplementary-material"}). The AORs for anemia were similar for increased age, ethnicity, and malaria infection at the time of enrolment, inflammation and ID as in the model without HIV. Human immunodeficiency virus infection led to a three-fold increased risk of anemia (AOR2.57, 95%CI 1.37--4.81). Increased MUAC was no longer significantly associated with increased risk of anemia after adjusting for HIV infection ([S1 Table](#pone.0208413.s001){ref-type="supplementary-material"}).

The risk of anemia gradually and in linear manner decreased with increasing MUAC and hip circumference but it increased with increasing age and CRP level. However, with a MUAC\<28cm, hip circumference\<95 cm, age \>28yearsand CRP \>10mg/L the prevalence of anemia was higher than the average prevalence of 36.7%. Finally, the risk of anemia steadily decreased with increasing ferritin levels up to 100μg/L and then flattened out, but the prevelence of anemia was above the average only at ferritin concentrations below 20μg/L ([Fig 2](#pone.0208413.g002){ref-type="fig"}).

![Trendline graphs of proportions of anemia by age, MUAC, hip circumference, s-ferritin and CRP among non-pregnant women in Korogwe.](pone.0208413.g002){#pone.0208413.g002}

Discussion {#sec014}
==========

The present study assessed the prevalenceand risk factors of preconceptionanemia in a cohort of rural Tanzanian women who were likely to conceive. In this study, a significant proportion of women had anemia and ID before conception. The prevalence of anemia in this study was similar to other community based studies among non pregnant women of reproductive age in Tanzania \[[@pone.0208413.ref007]\], Ethiopia \[[@pone.0208413.ref006]\] and Sierra Leone \[[@pone.0208413.ref008]\], which reported prevalence of anemia of 39.5%,30.4% and 44.8%, respectively,but with a wide variation in the prevalence of ID. In this study all women who were currently using modern contraceptives were excluded but the observed prevalence of anemia and ID were comparable to what Haile *et al*.\[[@pone.0208413.ref007]\] reported among non-pregnant Tanzanian women of reproductive age including hormonal contraceptive users. Since all women in this study were not using modern contraceptive methods and hence were likely to conceive, over one third are at risk of having anemia and/or suboptimal iron levels at the time of conception without interventions. The ID and anemia may further deteriorate during pregnancy in response to the increased physiologic demands of gestation, thereby increasing the risk of adverse pregnancy outcomes.

The risk of anemia decreased with increasing MUAC. Previous studies have also showed a negative correlation between anemia and MUAC \[[@pone.0208413.ref033],[@pone.0208413.ref034]\]. In low resource settings, MUAC has been shown to correctly identify undernourished or anemic women \[[@pone.0208413.ref035],[@pone.0208413.ref036]\], but there is no consensus on appropriate anthropometric cut-off points for risk prediction.Despite increasing adiposity being protective against anemia, pregnant women who are overweight or obese may face increased risk of numerous other complications, including gestational diabetes, pre-eclampsia, pregnancy-induced hypertension, stillbirths and preterm births \[[@pone.0208413.ref037]\]. Moreover, clustering of obesity and ID or anemia within the same individual poses a great challenge for public health interventions. In the current study, we found that nearly one third of overweight/obese women had concurrent anemia or ID. Furthermore, not until a MUAC \>28cm was the prevalence of anemia lower than the average of 36.7% indicating that some women are still anemic despite having a normal weight or only slight overweight. Therefore, specific interventions aimed at preventing anemia before conception should target all women of reproductive age, irrespective of their nutrition status.

Iron deficiency was common among both non-anemic as well as anemic women, but ID was associated with an almost five-fold increased risk of anemia. This finding is comparable to the recent study by Haile *et al*. \[[@pone.0208413.ref007]\] and underscores that adequate iron stores among women of the reproductive age is important and might be ensured by routine provision of iron and folic acid supplementation to all menstruating women, as recommended by the WHO \[[@pone.0208413.ref038]\].

Iron deficiency was characterized based on both RBC morphology (MCV and MCHC) and serum ferritin and compared, but a large proportion of the women with true ID would have been misclassified as not having ID based on RBC morphological patterns alone. This is not surprising as up to 40% of pure ID anemia may present with normocytic-normochromic pattern \[[@pone.0208413.ref039]\]. Moreover, the presence of microcytosis does not necessarily imply ID and can be present due to other causes such as thalassemias\[[@pone.0208413.ref040]\], or anemia of chronic disease \[[@pone.0208413.ref041]\]. Likewise, dimorphic anemia can occur in partially treated ID \[[@pone.0208413.ref041]\]. Serum ferritin is an acute phase reactant and can be increased if inflammation is present \[[@pone.0208413.ref042]\]. We applied the CF \[[@pone.0208413.ref026]\] to get a more precise estimate of ID in all women who had inflammation. Interestingly, the prevalence of ID using the CF did not differ significantly as compared to the two other used approaches (higher ferritin cut-off and or/ adjusting for high ALT) \[[@pone.0208413.ref042]\]. This was in contrast to a recent study by Namaste *et al*.\[[@pone.0208413.ref027]\] who reported a substantial underestimation of the burden of ID when only a higher ferritin cut-off approach was used as compared to adjusted approaches. One possible explanation for this difference could be the smaller sample size in our study compared to Namaste *et al*. study \[[@pone.0208413.ref027]\]. Haile *et al*. \[[@pone.0208413.ref007]\] excluded all malaria patients and used serum transferrin receptor (sTfR) as a marker of ID. However, sTfR can also be affected by acute inflammation \[[@pone.0208413.ref043],[@pone.0208413.ref044]\], and recently adjustment of sTfR using internal CF has been proposed \[[@pone.0208413.ref044]\]. Likewise, exclusion of all women with malaria would have introduced a selection bias.

A much higher prevalence of ID was observed as compared to Wirth *et al*. who reported a prevalence of ID of 8.3% among rural non-pregnant women of reproductive age in Sierra Leone despite a high prevalence of anemia (44.3%) \[[@pone.0208413.ref008]\]. The difference could be explained by a higher prevalence of malaria in Sierra Leone (23%) as compared to 8.1% in our study. Likewise, a recent meta-analysis has shown that the contribution of ID to the overall burden of anemia in women of reproductive age is much lower in regions with high burden of malaria and inflammation \[[@pone.0208413.ref005]\].

Although both malaria and HIV prevalence was below 10%, both were statistically significant risk factors for anemia and public health strategies should target these conditions. This should include screening and treatment to reduce the consequences for those already infected as well as preventive measures such as bed nets and condom usage in order to reduce the risk of infection. We also observe a trend towards a reduced risk of anemia for women who had previously used hormonal contraceptives. Similar, to our study, Haile *et al*., found that hormonal contraceptive use was significantly associated with a reduced risk of anemia and ID among non-pregnant women in Tanzania \[[@pone.0208413.ref007]\]. This might partially be due to reduced menstrual bleeding, as well as indicative of a higher socio-economic status and hence better health status among hormonal contraceptives users. For example, a recent report has shown that that 35% of women in the wealthiest households used modern contraceptive methods as compared to 20% among women from low income households \[[@pone.0208413.ref045]\].

The prevalence of STH infestations was very low and among the anemic women, none had infestations. This finding is similar to a previous study in this region which showed very low prevalence of STH (0.3%) among children in an urban settings \[[@pone.0208413.ref029]\]. The area participates in annual mass drug administration for control of lymphatic filariasis using ivermectin and albendazole as well as school deworming program. These programs may have shown additional impact on reduction of STH infestations.

Dietary iron absorption from the human gut is dependent on physiological requirements, but may be restricted by the quantity or bioavailability \[[@pone.0208413.ref046]\]. Whether IDin this population was primarily the result of dietary insufficiency or problems with absorption was beyond the scope of this paper. Understanding these patterns could provide important information about the relationship between food consumption and the risk of ID and anemia before conception in this setting. However, previous studies from a neighboring district of Muheza has shown that 73% of total iron intake came from staple food mainly cereals, fats and nuts and green leafy vegetables \[[@pone.0208413.ref046]\].In addition to low bioavailability, cereal staples contain iron absorption inhibitors, particularly tannins and phytates\[[@pone.0208413.ref046]\]. Therefore, high prevalence of ID without concurrent folate deficiency in our study could signify poor bioavailability rather than dietary insufficiency.

The Tanzanian government has strengthened different interventions to reduce the burden of anemia during pregnancy, including iron and folic acid supplementation, deworming, intermittent preventive treatment for malaria (IPTp) with sulfadoxine pyrimethamine as well as scaling up the coverage and usage of insecticide treated bed nets\[[@pone.0208413.ref045]\]. Furthermore, the Tanzanian National Multisectoral Nutrition Action Plan (2016--2021) aims to reduce the proportion of women of reproductive age with anemia from 45% to 33% through increased uptake of iron and folate supplements during pregnancy, increased acess to micronutrient powders from 10%-35% and increased proportion of iron fortified flour produced in Tanzania from 36%-50% \[[@pone.0208413.ref047]\]. However, despite anticipated benefits, the initiative has been compromised by high prevalence of pre-existing anemia and ID and short period of supplementation \[[@pone.0208413.ref045]\].Daily supplementation with 30--60 mg of elemental iron taken for three consecutive months in a year, is recommended by the WHO as a public health intervention to prevent anemia and ID for menstruatng women and adolescent girls living in settings where the prevalence of anemia 40% or higheror intermittent iron and folic acid supplementation in settings where prevelence of anemia is 20--40% \[[@pone.0208413.ref038]\]. However, despite its proven benefit, and recommendation by the WHO\[[@pone.0208413.ref038]\],preconception iron and folic acid supplementation has not been included in the current Tanzanian National Multisectora Nutrition Action Plan \[[@pone.0208413.ref047]\]. It is therefore worrisome that many anemic women willreceive these supplements only after conception and after having booked for antenatal care.

The strengths of the study include a large number of socio-demographic, economic, and clinical variables collected and stringent data monitoring system to ensure the quality of collected data. Furthermore, we could be rather certain that the cohort was truly preconception. For women who conceived during follow up, 85% had GA estimation in the first trimester. Pregnant women were excluded from analysis if the ultrasound examination demonstrated that they were already pregnant before conception or the GA was uncertain.

On the other hand, this study had several limitations. Firstly, the design of the main study was to identify women who would potentially conceive during the study period, especially women who were not using modern contraceptives. Women who were still using traditional contraceptive methods were included and their behavior and SES could be different from women who were actively trying to become pregnant. Secondly, serum ferritin level, which is also an acute phase protein, was used to detect ID. Serum ferritin levels were adjusted to account for the effect of inflammation by using internal CF and exclusion of all women without CRP measurement but this might not have corrected the entire effect. Further adjustment by using alfa1 acid glycoprotein in addition to CRP as marker of inflammation as well as using internal regression approach have also been proposed \[[@pone.0208413.ref027]\]. An alternative was to use sTfR, which is less affected by inflammation, but it was not available in this study. Thirdly, our study utilized serum sample to measure folate and B~12~ levels. The sensitivity of serum folate and vitamin B~12~ measurements for the diagnosis of clinically significant deficiency is uncertain because of the lack of a gold standard diagnostic method \[[@pone.0208413.ref048]\]. However, this may have had little effect on our estimate of the proportion of women with folate or vitamin B~12~ since previous studies have shown these deficiencies are responsible for a small proportion of anemia among women and children in SSA \[[@pone.0208413.ref007],[@pone.0208413.ref008]\]. Finally, the present study did not determine the burden of vitamin A deficiency is also a risk factor of anemia.

Conclusion {#sec015}
==========

The prevalence of preconception anemia and ID in this study population was high, while vitamin B~12~ and folate deficiencies were rare. Iron deficiency, malaria and HIV infections as well as inflammation were significantly associated with preconception anemia. This signifies that many women will enter pregnancy with depleted iron stores and/or anemia putting themselves and their growing fetus at risk. Therefore, concerted efforts, including intermittent iron and folic acid supplementation and nutrition counseling to improve iron status before conception for optimal fetal growth and newborn short and long-term health should also be considered in this population.
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